The Joint Venture with Novartis is a mess - Mitarbeiter (anonym) bei GSK: Mitarbeiterbewertung

3.0
9. Juni 2015
Mitarbeiter (anonym)
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Compensation, Big Brands, OTC Switch capability

Kontras

The Joint Venture with Novartis is all about cutting costs. The new GSK will be way too lean. I fear the GSK I know and love will be long gone in a few months. The transition will be long and difficult. Many things will fall trought the cracks and GSK will be less customer focused and even more focused on saving a buck. The poor performance of Big Pharma has made life difficult for Consumer Healthcare as we need to help the broader company keep the dividends high.

Mehr Bewertungen zu GSK entdecken

5.0
6. Mai 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Development Pay People Expertise Coaching

Kontras

Site management turnover lead to stability issues

1.0
9. Juni 2026
Empfehlen
CEO-Befürwortung
Geschäftsprognose

Pros

Fast paced work and a lot of very driven co-workers that are passionate about the work they do and delivering medicines to patients

Kontras

re-organization decimated the company culture. takes a long time to move up with the company. pay is considerably less compared to what other companies pay for role.

Bewertungen anzeigen nach: Hilfreich|Sterne|Datum|Alle